Abstract： Objective To explore the effect of durapeptide treatment of diabetic retinopathy on blood glucose and vi-sion level.Methods The clinical data of a total of 140 patients from May 2022 to July 2023 in the West China Xia-men Hospital of Sichuan University(Research Institute)were retrospectively analyzed,which were divided into(n=70)and study group(n=70)according different therapeutic drugs.The study group received subcutaneous durarantide in-jection.The clinical efficacy and adverse reactions of the two groups were compared.Before and after treatment,the blood glucose level[fasting plasma glucose(FPG),2-hour postprandial plasma glucose(2 hPG)],visual acuity level[naked eye vision,macular thickness bleeding spot area].Results After treatment,the therapeutic effect of the study group was better than that of the control group,and the difference was statistically significant(P<0.05).The levels of FPG and 2 hPG in the study group were lower than those in the control group,and the differences were statistically sig-nificant(both P<0.05).The visual acuity of the study group was higher than that of the control group,and the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse effects of the two groups(P>0.05).Conclusion Dragycopeptide can reduce blood glucose level,improve visual level and improve clini-cal efficacy in the treatment of diabetic retinopathy,and the risk of adverse reactions is relatively low.